Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by TNFRSF8 is a member of the TNF-receptor superfamily. Additionally we are shipping TNFRSF8 Kits (27) and TNFRSF8 Proteins (20) and many more products for this protein.
Showing 10 out of 658 products:
Human Monoclonal TNFRSF8 Primary Antibody for FACS, IHC (p) - ABIN94067
Pavlov, Martins, Delgado: Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing. in Clinical and vaccine immunology : CVI 2009
Show all 7 references for ABIN94067
Mouse (Murine) Monoclonal TNFRSF8 Primary Antibody for FACS - ABIN370914
Bowen, Lee, Miragliotta, Nam, Podack: Structure and expression of murine CD30 and its role in cytokine production. in Journal of immunology (Baltimore, Md. : 1950) 1996
Show all 3 references for ABIN370914
Mouse (Murine) Monoclonal TNFRSF8 Primary Antibody for FACS - ABIN370918
Falini, Pileri, Pizzolo, Dürkop, Flenghi, Stirpe, Martelli, Stein: CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. in Blood 1995
Show all 3 references for ABIN370918
Mouse (Murine) Monoclonal TNFRSF8 Primary Antibody for FACS - ABIN370913
Shanebeck, Maliszewski, Kennedy, Picha, Smith, Goodwin, Grabstein: Regulation of murine B cell growth and differentiation by CD30 ligand. in European journal of immunology 1995
Show all 3 references for ABIN370913
Human Monoclonal TNFRSF8 Primary Antibody for EIA, FACS - ABIN118590
Dürkop, Latza, Hummel, Eitelbach, Seed, Stein: Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. in Cell 1992
Show all 2 references for ABIN118590
Human Monoclonal TNFRSF8 Primary Antibody for FACS, ELISA - ABIN969019
Kamali, Abbasi, Farokhi, Abbasi, Fallah, Seifee, Ghadimi, Rezaie: Posttransplant soluble CD30 as a predictor of acute renal allograft rejection. in Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2010
This study demonstrated the amelioration of MOG35-55 peptide-induced active EAE in CD30 KO mice. CD30 was expressed limitedly on CD4 (show CD4 Antibodies) T cells at the induction phase of experimental autoimmune encephalomyelitis.
Data indicate that CD30L (show TNFSF8 Antibodies)/CD30 axis plays a modulatory role in the pathogenesis of experimental autoimmune encephalomyelitis (EAE).
role in the maintenance and activation of IL-17A (show IL17A Antibodies)-producing gammadelta T cells
These results suggest that CD30 signaling plays an important role in the activation of IL-17A (show IL17A Antibodies)-producing Vgamma1(-) Vgamma4(-) gammadelta T cells bearing Vgamma6 at an early stage of BCG (show SLC11A1 Antibodies) infection.
Interference of the CD30-CD30L (show TNFSF8 Antibodies) pathway reduces atherosclerosis development.
CD30L (show TNFSF8 Antibodies)/CD30 pathway acts as an accelerator of enteritis in a murine disease model
role of CD30L (show TNFSF8 Antibodies)/CD30 interactions in allergic rhinitis; results suggest that CD30L (show TNFSF8 Antibodies) plays an important role in allergic rhinitis
Abrogation of CD30 and OX40 (show TNFRSF4 Antibodies) signals prevents autoimmune disease in FoxP3 (show FOXP3 Antibodies)-deficient mice.
Studies demonstrate that CD30L (show TNFSF8 Antibodies)/CD30 signaling executed by the T-T cell interaction plays a critical role in Th17 cell differentiation.
CD30 can signal in a completely TCR-independent fashion to induce IL-13 (show IL13 Antibodies) production by effector T cells.
this study shows that polyclonal and allogeneic stimulation induced higher levels of CD30 transcripts in end-stage renal disease patients compared to control patients
CD30 expression was not associated with prognosis in our cohort of de novoDLBCL, including in patients who received aggressive chemotherapy. CD30 expression and MYC (show MYC Antibodies) rearrangement were mutually exclusive in de novoDLBCL.
Case Report: CD30 positive lymphomatoid papulosis arising in association with cutaneous amyloidosis in a patient with multiple myeloma.
The heterogeneity of CD30 expression in refractory or relapsed peripheral T-cell lymphoma patients indicates the likelihood for better response for patients with strong CD30 expression by tumor cells.
CD30 may be useful as a prognostic marker in rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP (show DDIT3 Antibodies)) treated DLBCLs, indicating favorable outcomes in a Chinese population.
this review is focused on the role of CD30 receptor and p53 (show TP53 Antibodies) as novel targets for therapy in ALK (show ALK Antibodies)+ ALCL, and also provides an update on their potential involvement in ALK (show ALK Antibodies)+ ALCL pathogenesis
Most angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma-not otherwise specified express variable levels of CD30.
Upregulated expression of CD30 is commonly found in sclerosing angiomatoid nodular transformation of the spleen.
Our results demonstrated significantly elevated sCD30 levels in AS patients compared to healthy controls (HCs (show HLCS Antibodies)) with mean values of 32.0 +/- 12.2 and 24.9 +/- 8.0 ng/mL, (P(**) = 0.007), suggesting a p role of sCD30 in the pathogenesis of AS.
With the introduction of the immunoconjugate brentuximab vedotin, the CD30 antigen has become an effectively targetable molecule. Therefore, we investigated the frequency and level of CD30 expression in post-transplant lymphoproliferative disorders.
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
tumor necrosis factor receptor superfamily member 8
, tumor necrosis factor receptor superfamily, member 8
, tumor necrosis factor ligand superfamily member 8
, tumor necrosis factor receptor superfamily member 8-like
, CD30L receptor
, lymphocyte activation antigen CD30
, Ki-1 antigen
, cytokine receptor CD30
, Tumor necrosis factor superfamily member 8
, tumor necrosis factor superfamily, member CD30